Disease severity and radioactive iodine use for thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 2, 2013, Pages 678-686

  Haymart, M R ^a,c   Muenz, D G ^c   Stewart, A K ^d   Griggs, J J ^b   Banerjee, M ^c  

^a Divisions of Metabolism Endocrinology and Diabetes and Hematology/Oncology ^*  (United States)

^b Division of Hematology/Oncology and Health Management and Policy   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d National Cancer Data Base   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE;

ADULT; ARTICLE; CANCER RISK; DISEASE SEVERITY; DRUG INDICATION; DRUG USE; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGIONALIZATION; RISK ASSESSMENT; THYROID CANCER; TREATMENT OUTCOME;

ADULT; CARCINOMA, PAPILLARY; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84873683157     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3160     Document Type: Article

References (42)

1. Haymart MR, Banerjee M, Stewart AK, Koenig RJ, Birkmeyer JD, Griggs JJ. Use of radioactive iodine for thyroid cancer. JAMA. 2011; 306:721-728.
2. Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011;117: 4439-4446.
3. Solans R, Bosch JA, Galofre P, et al. Salivary and lacrimal gland dysfunction (Sicca syndrome) after radioiodine therapy. J NuclMed. 2001;42:738-743.
4. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93:504-515.
5. Pace-Asciak PZ, Payne RJ, Eski SJ, Walfish P, Damani M, Freeman JL. Cost savings of patients with a MACIS score lower than 6 when radioactive iodine is not given. Arch Otolaryngol Head Neck Surg. 2007;133:870-873.
6. Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683-690.
7. Raval MV, Bilimoria KY, Stewart AK, Bentrem DJ, Ko CY. Using theNCDBfor cancer care improvement: an introduction to available quality assessment tools. J Surg Oncol. 2009;99:488-490.
8. Phillips JK, Stewart AK, ed. Facility Oncology Registry Data Standards. Chicago: Commission on Cancer; 2011.
9. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
10. Smedley BD, Stith AY, Nelson AR, ed. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. WA, DC: The National Academies Press; 2003.
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
12. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
13. Greene FL, ed. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002.
14. Fritz A, Jack A, Parkin DM, et al. ICD-O: International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
15. Snijders TAB, Bosker RJ. Multilevel Analysis. Thousand Oaks, CA: Sage; 1999.
16. Subramanian S, Jones K, Duncan C. Multilevel Methods for Public Health Research. New York, NY: Oxford University Press; 2003.
17. Haymart MR, Banerjee M, Yang D, et al. The relationship between extent of thyroid cancer surgery and use of radioactive iodine [published online ahead of print September 20, 2012]. Ann Surg. doi: 10.1097/SLA.0b013e31826c8915
18. Haymart MR, Banerjee M, Yang D, Stewart AK, Koenig RJ, Griggs JJ. The role of clinicians in determining radioactive iodine use for low-risk thyroid cancer [published online ahead of print June 28, 2012]. Cancer. doi: 10.1002/cncr. 27721
19. Solomon BL, Wartofsky L, Burman KD. Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab. 1996;81:333-339.
20. Sawka AM, Rotstein L, Brierley JD, et al. Regional differences in opinions on adjuvant radioactive iodine treatment of thyroid carcinoma within Canada and the United States. Thyroid. 2007;17: 1235-1242.
21. Bonnet S, Hartl D, Leboulleux S, et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab. 2009;94:1162-1167.
22. Hughes DT, White ML, Miller BS, Gauger PG, Burney RE, Doherty GM. Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery. 2010;148:1100-1106; discussion 1106-1107.
23. Teixeira G, Teixeira T, Gubert F, Chikota H, Tufano R. The incidence of central neck micrometastatic disease in patients with papillary thyroid cancer staged preoperatively and intraoperatively as N0. Surgery. 2011;150:1161-1167.
24. Cooper DS, Tufano RP. Prophylactic central neck dissection in differentiated thyroid cancer: a procedure in search of an indication. Thyroid. 2012;22:341-343.
25. Moreno MA, Edeiken-Monroe BS, Siegel ER, Sherman SI, Clayman GL. In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival. Thyroid. 2012;22:347-355.
26. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending. Part 1: the content, quality, and accessibility of care. Ann Intern Med. 2003;138:273-287.
27. Sirovich BE, Gottlieb DJ, Welch HG, Fisher ES. Regional variations in health care intensity and physician perceptions of quality of care. Ann Intern Med. 2006;144:641-649.
28. Roti E, Rossi R, Trasforini G, et al. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metab. 2006;91: 2171-2178.
29. Miccoli P, Minuto MN, Galleri D, et al. Incidental thyroid carcinoma in a large series of consecutive patients operated on for benign thyroid disease. ANZ J Surg. 2006;76:123-126.
30. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer. 1985;56:531-538.
31. Neuhold N, Schultheis A, Hermann M, Krotla G, Koperek O, Birner P. Incidental papillary microcarcinoma of the thyroid-further evidence of a very low malignant potential: a retrospective clinicopathological study with up to 30 years of follow-up. Ann Surg Oncol. 2011;18:3430-3436.
32. Cooper DS, Schneyer CR. Follicular and Hurthle cell carcinoma of the thyroid. Endocrinol Metab Clin North Am. 1990;19:577-591.
33. Machens A, Dralle H. Age disparities in referrals to specialist surgical care for papillary thyroid cancer. Eur J Surg Oncol. 2009;35: 1312-1317.
34. Park HS, Roman SA, Sosa JA. Treatment patterns of aging Americans with differentiated thyroid cancer. Cancer. 2010;116:20-30.
35. Sosa JA, Mehta PJ, Wang TS, Yeo HL, Roman SA. Racial disparities in clinical and economic outcomes from thyroidectomy. Ann Surg. 2007;246:1083-1091.
36. Griggs JJ, Sorbero ME, Ahrendt GM, et al. The pen and the scalpel: effect of diffusion of information on nonclinical variations in surgical treatment. Med Care. 2009;47:749-757.
37. Greenberg CC, Lipsitz SR, Neville B, et al. Receipt of appropriate surgical care for Medicare beneficiaries with cancer. Arch Surg. 2011;146:1128-1134.
38. Cooper DS, Doherty GM, Haugen BR, et al. Managementguidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109-142.
39. Schvartz C, Bonnetain F, Dabakuyo S, et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab. 2012;97:1526-1535.
40. Jonklaas J, Cooper DS, Ain KB, et al. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid. 2010;20: 1423-1424.
41. Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab. 1992;75:714-720.
42. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164-2167.